| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| InnovaTV 208 | 10-24 | Platinum Resistant epihtelial Ovarian cancer, primary peritoneal cancer or fallopian tube cancer. |
The study objectives are to evaluate the safety, antitumor activity, and pharmacokinetics of tisotumab vedotin (TV) for patients with epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has relapsed within 6 months of the completion of platinum-based treatment and determined to be platinum resistant. |
DSSG Group: Gynaecological
Soraya
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| Soraya | 20-06 | platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of Folate Receptor-Alpha (FRα). |
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) |
ENGOT EN-9
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| ENGOT EN-9 | CTRIAL-IE 19-20 | Advanced or recurrent endometrial carcinoma |
This study will assess the anti-tumour activity of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK7902) Versus Chemotherapy for first line treatment. |
PORTEC-4a
| Name | No. | For Patients with | Purpose |
|---|---|---|---|
| PORTEC-4a | CTRIAL-IE 18-27 | Early stage endometrial cancer |
The purpose of this study is to look at rates of vaginal recurrence in patients treated after surgery for their endometrial cancer with either external beam radiation therapy, brachytherapy or no additional treatment, based on a molecular test,in the investigational molecular arm or with brachytherapy in the standard arm. |